Diagnosis and Predictors of Treatment Outcomes in Atypical and Anaplastic Meningiomas

Atypical and anaplastic meningiomas (WHO grade II and III) are uncommon tumors with poorer prognosis than benign meningiomas. They represent a small and heterogeneous subgroup of meningiomas that has more aggressive biological nature and higher frequency of recurrence. Atypical form accounts for 4.7–7.2%, whereas the anaplastic type accounts for 1–2.8% of all meningiomas. Treatment of atypical/anaplastic meningiomas remains challenging. The extent of resection and histological grade are the key determinants for prognosis. Recurrence rates even after gross total resection remain high. Postoperative radiation therapy increases progression-free survival as well as overall survival. The role of stereotactic radiosurgery is increasing. Various chemotherapy treatments have shown some efficacy but there are no effective chemotherapeutic agents available. In the present study, we evaluate predictors of treatment outcomes of patients with atypical and malignant meningiomas treated at the Neurological Institute of Curitiba, Brazil, in the last 10 years. This study is based on the histopathological findings according to WHO 2016 classification, age, tumor size and location, and brain invasion.

Die Autoren geben an, dass kein Interessenkonflikt besteht.